Study of Aldosterone Hormone and Kidney Risk in Diabetes
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is studying how a common hormonal condition (primary aldosteronism) affects kidney risk in people with diabetes or prediabetes. It may help doctors better protect kidneys from damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have type 2 diabetes or are at risk for it based on your blood sugar levels.
- Your kidneys are starting to show signs of trouble, like slightly lower function or protein in urine, or you have a high BMI or high blood pressure.
- You do not have severe heart problems, active cancer, or certain other serious health issues.
- You are not pregnant or breastfeeding, and you do not use illegal drugs or certain medications like daily opioids or steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how different foods affect kidney health in people with type 2 diabetes and early kidney disease. Researchers will compare dietary patterns across different ethnic groups to understand what helps protect kidneys.
This study tests whether starting four blood-pressure and kidney-protective medications at the same time is safe and effective for people with type 2 diabetes and early kidney disease. The goal is to slow kidney damage and reduce heart and kidney problems.
This Phase 2 study tests whether adding NAD can improve kidney health in people with diabetes-related kidney disease. It is designed for people with certain urine lab results showing kidney stress, while keeping blood sugar and safety limits within range.
This study tests a personalized medication approach to lower kidney and heart risks in people with type 2 diabetes and early-to-moderate kidney disease. It may help you if you have a high chance of heart problems and can start new medications.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.